6-[3-(2-hydroxy-1-methyl-ethylcarbamoyl)-phenyl]-hex-5-ynoic acid methyl ester | 863713-64-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-[3-(2-hydroxy-1-methyl-ethylcarbamoyl)-phenyl]-hex-5-ynoic acid methyl ester
• 英文别名: Methyl 6-[3-(1-hydroxypropan-2-ylcarbamoyl)phenyl]hex-5-ynoate
• CAS: 863713-64-8
• 化学式: C₁₇H₂₁NO₄
• 分子量: 303.358
• InChiKey: STQCCXKHAOAJQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  甲醇 、 5-己炔酸 在 copper(l) iodide 、 四(三苯基膦)钯 四氢吡咯 作用下， 反应 3.63h， 以85%的产率得到6-[3-(2-hydroxy-1-methyl-ethylcarbamoyl)-phenyl]-hex-5-ynoic acid methyl ester
  参考文献：
  名称：

  [EN] MODULATORS OF CANNABINOID RECEPTORS
  [FR] MODULATEUR

  摘要：

  公开号：

  WO2005080316A3

文献信息

• [EN] COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À LA MODULATION DU CANAL BK
  申请人：CANBEX THERAPEUTICS LTD

  公开号：WO2016128771A1

  公开（公告）日：2016-08-18

  The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein: Z is OR16 or NR17R18; R16 is H or alkyl; R17 is H or alkyl; R18 is alkyl or cycloalkyl, each of which is optionally substituted by one or more substituents selected from OH, halogen and COOR11; X is a group selected from -C≡C-

  本发明涉及一种式I的化合物，或其药学上可接受的盐、溶剂或前药，其中：Z为OR16或NR17R18；R16为H或烷基；R17为H或烷基；R18为烷基或环烷基，每个烷基或环烷基可选择地被一个或多个OH、卤素和COOR11取代；X为从-C≡C-<(CH2)P-；-C
• Modulator
  申请人：Okuyama Masahiro

  公开号：US20080114062A1

  公开（公告）日：2008-05-15

  The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR 1 or NR 1 R 2 wherein each of R 1 and R 2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO 2 -alkyl, alkenyl, CN, NH 2 , hydroxy, halo, alkoxy, CF 3 and nitro; Y is a polar functional group selected from OH, NO 2 , CN, COR 3 , COOR 3 , NR 3 R 4 , CONR 3 R 4 , SO 3 H, SO 2 —R 3 , SO 2 NR 3 R 4 and CF 3 , where each of R 3 and R 4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH2) n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X—Y is other than meta-C≡—C—(CH 2 ) 2 CO 2 H, meta-C≡—C—(CH 2 ) 2 OH, meta-C≡C—(CH 2 ) 2 CO 2 Me, meta-(CH 2 ) 4 CO 2 H, ortho-CH 2 CO 2 H, ortho-(CH 2 ) 2 CO 2 H and ortho-(CH 2 ) 4 CO 2 H; and (ii) when A is phenyl, n is 0, and Z is OMe, X—Y is other than meta-C≡C—(CH 2 ) 4 OH. Further aspects of the invention relate to the use of such compounds in the preparation of a medicament for the treatment of a muscular disorder, a gastrointestinal disorder, or for controlling spasticity or tremors.

  本发明涉及公式(I)的化合物或其药学上可接受的盐，其中Z为OR1或NR1R2，其中R1和R2各自独立地为H或烃基；X为烷基，烯基或炔基，每个基团可以选择性地被一个或多个取代基所取代，所述取代基包括烷基，COOH，CO2-烷基，烯基，CN，NH2，羟基，卤素，烷氧基，CF3和硝基；Y为极性官能团，选自OH，NO2，CN，COR3，COOR3，NR3R4，CONR3R4，SO3H，SO2—R3，SO2NR3R4和CF3，其中R3和R4各自独立地为H或烃基；A为芳基或杂环芳基，每个基团可以选择性地被取代；B为(CH2)n，其中n为0、1、2、3、4或5；条件是：（i）当A为苯基，n为0，且Z为OH时，X-Y不为间位-C≡—C—（CH2）2CO2H、间位-C≡—C—（CH2）2OH、间位-C≡C—（CH2）2CO2Me、间位-（CH2）4CO2H、邻位-CH2CO2H、邻位-（CH2）2CO2H和邻位-（CH2）4CO2H；（ii）当A为苯基，n为0，且Z为OMe时，X-Y不为间位-C≡C—（CH2）4OH。本发明的进一步方面涉及将这些化合物用于制备用于治疗肌肉障碍、胃肠障碍或控制痉挛或震颤的药物。
• MODULATOR
  申请人：Okuyama Masahiro

  公开号：US20100144876A1

  公开（公告）日：2010-06-10

  The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR 1 or NR 1 R 2 wherein each of R 1 and R 2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO 2 -alkyl, alkenyl, CN, NH 2 , hydroxy, halo, alkoxy, CF 3 and nitro; Y is a polar functional group selected from OH, NO 2 , CN, COR 3 , COOR 3 , NR 3 R 4 , CONR 3 R 4 , SO 3 H, SO 2 —R 3 , SO 2 NR 3 R 4 and CF 3 , where each of R 3 and R 4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH 2 ) n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X—Y is other than meta-C≡—C—(CH 2 ) 2 CO 2 H, meta-C≡—C—(CH 2 ) 2 OH, meta-C≡C—(CH 2 ) 2 CO 2 Me, meta-(CH 2 ) 4 CO 2 H, ortho-CH 2 CO 2 H, ortho-(CH 2 ) 2 CO 2 H and ortho-(CH 2 ) 4 CO 2 H; and (ii) when A is phenyl, n is 0, and Z is OMe, X—Y is other than meta-C≡C—(CH 2 ) 4 OH. Further aspects of the invention relate to the use of such compounds in the preparation of a medicament for the treatment of a muscular disorder, a gastrointestinal disorder, or for controlling spasticity or tremors.

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中Z为OR1或NR1R2，其中R1和R2各自独立地为H或烃基；X为可选地由烷基，COOH，CO2-烷基，烯基，CN，NH2，羟基，卤素，烷氧基，CF3和硝基中的一个或多个取代的烷基，烯基或炔基基团；Y为从OH，NO2，CN，COR3，COOR3，NR3R4，CONR3R4，SO3H，SO2—R3，SO2NR3R4和CF3中选择的极性官能团，其中R3和R4各自独立地为H或烃基；A为可选地取代的芳基或杂环基团；B为（CH2）n，其中n为0、1、2、3、4或5；但有以下规定：（i）当A为苯基，n为0，且Z为OH时，X—Y不是间位-C≡—C—（CH2）2CO2H，间位-C≡—C—（CH2）2OH，间位-C≡C—（CH2）2CO2Me，间位-（CH2）4CO2H，邻位-CH2CO2H，邻位-（CH2）2CO2H和邻位-（CH2）4CO2H；（ii）当A为苯基，n为0，且Z为OMe时，X—Y不是间位-C≡C—（CH2）4OH。本发明的进一步方面涉及使用这些化合物制备治疗肌肉障碍，胃肠障碍或控制痉挛或震颤的药物。
• MODULATORS OF CANNABINOID RECEPTORS
  申请人：UCL Biomedica plc

  公开号：EP1745011A2

  公开（公告）日：2007-01-24
• COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION
  申请人：Canbex Therapeutics Limited

  公开号：US20180116983A1

  公开（公告）日：2018-05-03

  The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein: Z is OR 16 or NR 17 R 18 ; R 16 is H or alkyl; R 17 is H or alkyl; R 18 is alkyl or cycloalkyl, each of which is optionally substituted by one or more substituents selected from OH, halogen and COOR 11 ; X is a group selected from —C≡C—